Answers are grounded in this paper and cite their sources.
INTRODUCTION: Electronic cigarettes (e-cigarettes) are widely used for smoking cessation or harm reduction, but their potential long-term health effects remain uncertain. Biomarkers of potential harm (BOPH) can provide early insight into biological effects of exposure before clinical disease develops. We studied whether acute e-cigarette use alters circulating biomarkers related to inflammation, endothelial activation, and lung injury. METHODS: Twenty-three adult regular e-cigarette users participated in a two-arm counterbalanced crossover study, of whom 20 had complete data for both product conditions and were included in the primary analysis. On separate study days, participants used either their usual brand (UB) e-cigarette or a standardized research electronic cigarette (SREC) provided through the National Institute on Drug Abuse. Each study day included a 5-minute standardized vaping session followed by a 3-hour ad libitum use session. Plasma concentrations of IL-6, IL-8, ICAM-1, TNFR1, RAGE, and ANG2 were measured before and at various times after use. Biomarker responses were analyzed using repeated-measures analyses on log-transformed data. RESULTS: No significant changes were observed in any biomarkers after the standardized or ad libitum vaping sessions (all p > .05). Responses were similar between the SREC device and participants' UB devices. CONCLUSIONS: In regular e-cigarette users, acute vaping sessions did not produce significant changes in biomarkers of inflammation, endothelial activation, or epithelial injury. These findings indicate that short-term e-cigarette use in habitual vapers does not produce detectable acute systemic inflammatory responses. Whether longer-term vaping produces adverse changes in BOPH remains to be determined.
No takes yet. Share an insight, caveat, or question.
Nosseir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: